Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while ...
Hosted on MSN21h
Equifax (EFX) Earnings Expected to Grow: Should You Buy?Wall Street expects a year-over-year increase in earnings on higher revenues when Equifax (EFX) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
Morgan Stanley lowered the firm’s price target on Equifax (EFX) to $316 from $320 and keeps an Overweight rating on the shares. While the firm ...
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb Symmetry trial testing ...
Akero Therapeutics (AKRO) stock soared 115% after the company reported positive long-term results from a Phase 2b study of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback